Antitumor activity of ionic niobocene and molybdenocene complexes in high oxidation states
- PMID: 1548287
- PMCID: PMC12201800
- DOI: 10.1007/BF01410137
Antitumor activity of ionic niobocene and molybdenocene complexes in high oxidation states
Abstract
Four air-stable niobocene complexes [(C5H5)2NbCl2]+X- with X = BF4, AsF6, SbF6, SO3CF3 and the molybdenocene derivative [(C5H5)2MoCl2]2+[SbF6]2- were investigated for antitumor properties against Ehrlich ascites tumor in female CF1 mice. All compounds are new, salt-like complexes containing a cationic metallocene moiety, where the early transition metals niobium and molybdenum in the high oxidation states +5 and +6 function as central atoms. The niobocene complexes containing tetrafluoroborate (BF4-) or trifluoromethanesulfonate (CF3SO3-) as anions only induced a maximal cure rate of 50% and led to increases in life span of 182% and 178% following application of optimal doses. The other two niobocene compounds with hexafluoroarsenate (AsF6-) and hexafluoroantimonate (SbF6-) as anions and the molybdenocene derivative [(C5H5)2MoCl2]2+[SbF6]2- effected a maximal cure rate of 100% and increases in life span of 346%, 376%, and 332%, respectively, determined on the key date, i.e., on day 90 after transplantation. On applying the niobocene hexafluoroantimonate complex [(C5H5)2NbCl2] +[SbF6]-, the optimal dose range with a cure rate of 100% was rather broad and extended from 20 mg/kg to 40 mg/kg. Correspondingly, the value of the therapeutic index (TI) was high and amounted to 7.2. In the case of the niobocene hexafluoroarsenate and the molybdenocene hexafluoroantimonate complexes, the TI value decreased to 5.3 and 2.6 respectively. Neither impairments of the general condition nor any conspicuous symptoms could be detected after application of therapeutic doses of the five compounds investigated. Compared to the neutral niobocene dichloro complex [(C5H5)2NbCl2], the therapeutic range of the ionic niobocene derivative [(C5H5)2NbCl2]+[SbF6]- was broadened, the TI value markedly elevated from 2.9 to 7.2, and the toxic symptoms were impressively reduced. The niobocene hexafluoroantimonate complex was the most effective compound investigated in the present study.
Similar articles
-
Ionic rhenocene derivatives with antitumor activity.Cancer Chemother Pharmacol. 1992;29(5):361-6. doi: 10.1007/BF00686004. Cancer Chemother Pharmacol. 1992. PMID: 1551174
-
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.Cochrane Database Syst Rev. 2020 Oct 19;10(10):CD012859. doi: 10.1002/14651858.CD012859.pub2. Cochrane Database Syst Rev. 2020. PMID: 33075160 Free PMC article.
-
The Black Book of Psychotropic Dosing and Monitoring.Psychopharmacol Bull. 2024 Jul 8;54(3):8-59. Psychopharmacol Bull. 2024. PMID: 38993656 Free PMC article. Review.
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280. Health Technol Assess. 2001. PMID: 11701100
-
Etanercept and efalizumab for the treatment of psoriasis: a systematic review.Health Technol Assess. 2006 Nov;10(46):1-233, i-iv. doi: 10.3310/hta10460. Health Technol Assess. 2006. PMID: 17083854
Cited by
-
Niobium uptake and release by bacterial ferric ion binding protein.Bioinorg Chem Appl. 2010;2010:307578. doi: 10.1155/2010/307578. Epub 2010 Apr 28. Bioinorg Chem Appl. 2010. PMID: 20445753 Free PMC article.
-
Complexes of metals other than platinum as antitumour agents.Eur J Clin Pharmacol. 1994;47(1):1-16. doi: 10.1007/BF00193472. Eur J Clin Pharmacol. 1994. PMID: 7988618 Review.
-
Water-soluble molybdenocene complexes with both proliferative and antiproliferative effects on cancer cell lines and their binding interactions with human serum albumin.J Biol Inorg Chem. 2009 Sep;14(7):1109-17. doi: 10.1007/s00775-009-0554-0. Epub 2009 Jun 18. J Biol Inorg Chem. 2009. PMID: 19536567 Free PMC article.
-
Bioorganometallic Chemistry of Molybdenocene Dichloride and Its Derivatives.J Organomet Chem. 2012 Jun 1;706-707:4-12. doi: 10.1016/j.jorganchem.2012.02.006. Epub 2012 Feb 6. J Organomet Chem. 2012. PMID: 22605891 Free PMC article.
References
-
- Clearfield A, Warner DK, Saldarriaga-Molina CH, Ropal R, Bernal I (1975) Structural studies of(π-C5H5)2MX2 complexes and their derivatives. The structure of bis(π-cyclopentadienyl)titanium dichloride. Can J Chem 53:1622–1629
-
- Gowik P, Klapötke T (1989) Organo-Übergangsmetall-Chemie hochfluorierter Ligand-Systeme: X. Neue Organoniob(V)-perfluoroborat-,-arsenat- und antimonat-Komplexe. J Organomet Chem 368:35–44
-
- Gowik P, Klapötke T, Pickardt J (1989a) Quantitative oxidation of organovanadium(IV) and-niobium(IV) complexes: synthesis of Cp2V(SbF6)2, [Cp2VCl2][AsF6], and [Cp2V(AsF6)2][AsF6]. Crystal structure of [Cp2NbCl2][SbF6]. Organometallics 8:2953–2956
-
- Gowik P, Klapötke T, White P (1989b) Dikationen des Molybdänocen(VI)-und Wolframocen(VI)-dichlorids. Chem Ber 122:1649–1650
-
- Gowik P, Klapötke T, Thewalt U (1990) Metallocen-Chemie hochfluorierter Ligand-Systeme: XI. Synthese und Charakterisierung von Cp2Ti(SbF6)2 und Cp2Ti(Sb2F11)2; Struktur von Cp2Ti(SbF6)2 und Cp2V(SbF6)2. J Organomet Chem 385:345–350
MeSH terms
Substances
LinkOut - more resources
Full Text Sources